(Q44298568)

1 December 2017

title

Correlation between CA-125 serum level and response by RECIST in a phase III recurrent ovarian cancer study (English)

1 reference

1 December 2017

1 reference

12

Bradley J Monk

1 reference

1 December 2017

Thomas J Herzog

1

1 reference

1 December 2017

Jan B Vermorken

2

1 reference

1 December 2017

Eric Pujade-Lauraine

3

1 reference

1 December 2017

Diane M Provencher

4

1 reference

1 December 2017

Agnieszka Jagiello-Gruszfeld

5

1 reference

1 December 2017

Beihua Kong

6

1 reference

1 December 2017

Karin Boman

7

1 reference

1 December 2017

Youn Choi Park

8

1 reference

1 December 2017

Trilok Parekh

9

1 reference

1 December 2017

Claudia Lebedinsky

10

1 reference

1 December 2017

Javier Gómez

11

1 reference

1 December 2017

language of work or name

English

0 references

publication date

5 May 2011

1 reference

1 December 2017

1 reference

1 December 2017

volume

122

1 reference

1 December 2017

issue

2

1 reference

1 December 2017

page(s)

350-355

1 reference

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

1 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.04.005

Frequency of symptoms of ovarian cancer in women presenting to primary care clinics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.04.005

Development of an ovarian cancer symptom index: possibilities for earlier detection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.04.005

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.04.005

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.04.005

Reporting results of cancer treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.04.005

Toxicity of MRI and CT contrast agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.04.005

Interobserver and intraobserver variability in the response evaluation of cancer therapy according to RECIST and WHO-criteria.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.04.005

Trabectedin: a review of its use in soft tissue sarcoma and ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.04.005

A review of trabectedin (ET-743): a unique mechanism of action.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.04.005

Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.04.005

Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.04.005

Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.04.005

Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.04.005

Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.04.005

Biological variation and analytical imprecision of CA 125 in patients with ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.04.005

A Coefficient of Agreement for Nominal Scales

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.04.005

Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.04.005

Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.04.005

Prognostic role of Ca125 response criteria and RECIST criteria: analysis of results from the MITO-3 phase III trial of gemcitabine versus pegylated liposomal doxorubicin in recurrent ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.04.005

Should CA-125 response criteria be preferred to response evaluation criteria in solid tumors (RECIST) for prognostication during second-line chemotherapy of ovarian carcinoma?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.04.005

Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.04.005

Modulation of 5-fluorouracil with high-dose leucovorin calcium: activity in ovarian cancer and correlation with CA-125 levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.04.005

CA 125: a valid marker in ovarian carcinoma patients treated with paclitaxel?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.04.005

Early changes in CA125 after treatment with pegylated liposomal doxorubicin or topotecan do not always reflect best response in recurrent ovarian cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.04.005

Early CA-125 fluctuations in patients with recurrent ovarian cancer receiving chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.04.005

CA-125 response in patients with recurrent ovarian or primary peritoneal cancer treated with pegylated liposomal doxorubicin or topotecan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.04.005

10.1016/J.YGYNO.2011.04.005

7 January 2021

Identifiers

DOI

1 reference

release_tar4xjrssvbfdeokblszgiixzy

1 December 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/tar4xjrssvbfdeokblszgiixzy

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference